Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25003166 | 1.00 | FDPS (0.47) | FDPSMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27237391 | 1.00 | FDPS (0.47) | FDPSMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27237488 | 0.88 | HDAC6 (0.47) | MAPTSMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL25002987 | 0.88 | HDAC6 (0.47) | MAPTSMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL30171377 | 0.85 | MAPT (0.52) | MAPTSMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL25002958 | 0.85 | MAPT (0.52) | MAPTSMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL27237434 | 0.85 | MAPT (0.52) | MAPTSMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL25002954 | 0.84 | ALDH1A1 (0.50) | MAPTSMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL30862201 | 0.84 | ALDH1A1 (0.50) | MAPTSMN1; SMN2KMT2AMEN1RAB9A | |
| SCHEMBL27237475 | 0.84 | ALDH1A1 (0.50) | MAPTSMN1; SMN2KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335420-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-10-10 | — | — | US | claimed |
| US-20240335420-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-10-10 | — | — | US | disclosed |
| EP-4382101-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2024-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335420-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS | SCN1A, SCN1B, CACNA1B | FDPS 2743/4885MAPT 4081/4885SMN1; SMN2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.